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Background: Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF)
gene are present in approximately 50% of melanomas. The selective BRAF inhibitor vemurafenib has demonstrated
significant clinical benefits in patients with melanomas harboring the most common mutations (V600E, V600K and
V600R). However, the clinical activity of BRAF inhibitors in patients with rare mutations of codon 600 and the
surrounding codons has not been documented.
Case presentation: We used the BRAF inhibitor vemurafenib to treat a patient presenting a rare p.
V600_K601delinsD-mutated melanoma. An objective response was evidenced by two months of progression-free
survival. By cloning and sequencing BRAF exon 15, we confirmed that a dual mutation was present on a single allele
and thus resulted in a BRAFV600DK601del mutant protein. We also performed an in silico crystal structure analysis of the
mutated protein, in order to characterize the nature of the putative interaction between vemurafenib and the
mutant protein.
Conclusion: This clinical experience suggests that (i) patients with BRAFV600DK601del-mutation-positive melanoma can
be treated successfully with the oral BRAF inhibitor vemurafenib and (ii) molecular screening in this context should
encompass rare and complex mutations.
Keywords: Metastatic melanoma, Rare BRAF mutations, Monoallelic mutation, V600E, V600DK601del, Crystal
structures, BRAF inhibitor, VemurafenibBackground
Melanoma is the malignancy with the highest prevalence
of BRAF gene mutations. The most frequent BRAF muta-
tion is a substitution at the second position of codon 600
(GTG>GAG), c.1799 T >A), which results in an amino
acid change from valine (V) to glutamic acid (E) (p.V600E).
In the initial study by Davies et al. [1], the p.V600E muta-
tion accounted for more than 90% of BRAF mutations. Al-
though the high frequency of BRAF mutations (and
particularly the p.V600E mutation) in melanoma has been* Correspondence: trudel.stephanie@chu-amiens.fr
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unless otherwise stated.confirmed in all subsequent studies (for a review, see [2,3]),
its incidence is usually somewhat lower than initially
reported. In fact, large, recent studies have shown that the
p.V600E genotype is not as prevalent as expected and that
p.V600K and p.V600R respectively account for 17%-22%
and 3%-4% of the BRAF mutation-positive melanoma
population [4,5]. Moreover, less frequent mutations were
subsequently reported by other researchers, including other
codon 600 mutations (p.V600E2 and p.V600D/M/G) and
mutations in codons in the vicinity of codon 600 (such as
p.D594N/V, p.G596R, p.L597R/V/S/Q and p.K601E/N)
[4-11]. These “orphan” non-p.V600E/K/R mutations ac-
count for approximately 6% of all mutations reported for
melanoma in the COSMIC database [12].
In terms of structural and functional aspects, the acti-
vation segment of BRAF’s kinase domain binds to the P-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ticular, the valine at position 600 (within the activation
segment) is thought to hold the protein in an inactive con-
formation [13]. In the BRAFV600E mutant protein, the
hydrophobic valine is replaced by a glutamic acid residue,
which disrupts the interaction between the activation seg-
ment and the P-loop and leads to a marked increase in
kinase activity [13].
Advances in the molecular characterization of melan-
oma and BRAFV600E mutant protein and better know-
ledge of the BRAF signaling cascade have enabled the
development of therapeutic BRAF-kinase inhibitors that
target the constitutively active mutant BRAF protein.
Vemurafenib (formerly PLX-4032) was specifically de-
signed to target BRAF protein kinase with the oncogenic
mutation p.V600E [14] and received marketing approval
in the USA and Europe in 2011. The drug is licensed as
a monotherapy for patients with advanced melanoma
harboring a BRAFV600 mutation.
In various prospective studies, vemurafenib has demon-
strated significant clinical benefits in patient with p.V600E
BRAF-mutation-positive metastatic melanoma. The re-
sponse rate (according to the Response Evaluation Criteria
In Solid Tumors (RECIST) criteria) is approximately 50%,
and vemurafenib treatment is associated with prolonged
progression-free survival (PFS) and overall survival when
compared with the reference standard treatment (dacarba-
zine-based chemotherapy) [15-17]. A few reports have
suggested that melanoma harboring a p.V600K or a p.
V600R mutation may also respond to vemurafenib therapy
[17-19]. However, it is not yet clear whether BRAF inhibi-
tors are effective in patients with rare-mutation-positive
melanoma. With the exception of scarce in vitro data,
there is no evidence to suggest that selective BRAF inhibi-
tors show clinical activity against orphan non-p.V600E/K/
R mutations and so clinical efficacy is not well established.
Here, we report the case of a patient with metastatic
melanoma harboring a rare and complex BRAF muta-
tion. A course of vemurafenib therapy was associated
with two months of PFS. We also performed molecular
characterization of the mutation and an in silico crystal
structure analysis of the mutated BRAF domain.
Case presentation
Clinical course and pathological features
In February 2007, a 66 year-old woman was diagnosed as
having a 2.35 mm cutaneous nodular thoracic melanoma
and underwent complete excision with 2 cm margins. In
March 2012, routine monitoring with computed tomog-
raphy (CT) revealed two metastatic pulmonary nodes in
the left upper and lower lobes. The subsequent patho-
logical diagnosis (based on analysis of the two wedge-
resections) was malignant melanoma. Genetic testing of
the patient’s pulmonary metastases identified a p.V600EBRAF mutation, making the patient eligible for a targeted
therapy with an oral BRAF inhibitor. In July 2012, the dis-
ease had progressed to stage IV with bone, pulmonary,
liver and brain metastases, as revealed by lower back pain.
The patient was then treated with the BRAF inhibitor
vemurafenib (960 mg per os, twice daily). After four
weeks of treatment, the patient’s general health status
had improved and the lower back pain was less intense.
Computed tomography imaging revealed stable disease,
according to RECIST criteria (with a 25% decrease in
the size of the metastases, Figure 1). Eight weeks after
the initiation of vemurafenib treatment, the patient pre-
sented a deterioration in general health status and an
elevation of liver transaminases and lactate dehydrogen-
ase levels. The vemurafenib treatment was maintained
but the dose was reduced to 720 mg per os twice daily.
In view of the disease progression and the emergence of
side effects and diffuse bone pain, vemurafenib was
withdrawn after 12 weeks of treatment. Palliative care
was administered. A month later, the patient died from
the progression of metastatic disease.
Molecular analysis
The initial diagnostic testing for BRAF mutations was
performed by primer extension reaction (BRAF mutation
analysis reagents, Applied Biosystems, CA, USA). The
extension primer specifically targets the second nucleo-
tide in codon 600 of BRAF gene, enabling the detection
of p.V600E (GTG >GAG), p.V600G (GTG >GGG) or p.
V600A (GTG >GCG) mutations but not mutations that
also involve nucleotides at positions 1 or 3 (such as p.
V600K (GTG >AAG) and p.V600D (GTG >GAT)). The
primer extension products were separated by capillary
electrophoresis on a 3500 xL Dx Genetic Analyzer (Ap-
plied Biosystems, CA, USA) and then underwent fragment
analysis using Gene Mapper v4.1 software (Applied Bio-
systems, CA, USA). As shown in Figure 2, a peak corre-
sponding to the p.V600E mutation (a thymine to adenine
substitution at position 1799 (c.1799 T > A)) was detected
in the patient’s tumor cells.
The presence of the p.V600E mutation was confirmed
by bidirectional sequencing of BRAF exon 15 using an
ABI PRISM Big Dye Termination Cycle Sequencing kit
v1.1 (Applied Biosystems, CA, USA), a 3500 xL Dx Gen-
etic Analyzer and Sequencing Analysis software v5.4 (Ap-
plied Biosystems, CA, USA).
Surprisingly, sequence analysis revealed that the mu-
tation was more complex than a single nucleotide sub-
stitution (Figure 3A). The electropherogram showed an
overlapping pattern starting at position 1799, which most
probably indicates a heterozygous deletion and/or insertion.
By comparing the overlapping sequence with the BRAF
gene’s reference sequence (NM_004333.4), we found
that the mutation corresponds to c.1799_1803delinsAT
A B
Figure 1 Computed tomography. The figures shows the initial CT scan of the liver (performed at the time that the metastatic stage of the
disease was diagnosed) (A) and a CT scan acquired 4 weeks after the initiation of vemurafenib treatment (B). The metastasis is indicated by an
arrow. Comparison of the two scans reveals a partial regression of the metastatic tumor.
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Genome Variation Society-approved nomenclature
[20]. At the protein level, this results in substitution of
the valine (V) at position 600 by an aspartic acid (D)
and the deletion of the lysine (K) at position 601
(BRAFV600DK601del). However, the identification of a





Figure 2 Primer extension and fragment analysis. Representative electr
and wild type controls (A), tumor DNA from a melanoma patient without
mutation (C).of multiple cells does not necessarily mean that the
two mutations are carried by a unique allele; they may
correspond to two alleles in a single tumor clone or
even to two individual tumor clones. This distinction is
important because it would probably result in a signifi-
cant difference in the therapeutic response to vemura-
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Figure 3 Sequence analysis of BRAF exon 15. Electropherograms from direct sequencing of the tumor’s genomic DNA (A), displaying an
overlapping pattern starting from nucleotide 1799 (indicated by an arrow) and cloned PCR products (B) showing the wild type allele (left) and
the c.1799_1803delinsAT mutation (right) that leads to amino acid substitution and deletion (p.V600_K601delinsD).
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whether the mutation was monoallelic (BRAFV600DK601del)
or biallelic (BRAFV600D and BRAFK601del), we applied a TA
cloning-based sequencing method. The polymerase chain
reaction (PCR) products from BRAF exon 15 amplification
were cloned into a pCR™2.1 vector with the TA Cloning®
Kit (Invitrogen, CA, USA) and the inserts were sequenced
using the M13 forward and reverse primers.
Comparison of the electropherograms (Figure 3B and
C) showed that one allele was wild type and that the
other was mutated. In the mutant allele, thymine (T)
and guanine (G) at positions 1799 and 1800 had been re-
spectively replaced by adenine (A) and thymine (T). The
substitutions had been followed by an in-frame deletion
of three adenines (AAA). Hence, the mutation was a
monoallelic event that resulted in a protein product with
a valine to aspartic acid substitution at position 600 and
an in-frame deletion of the lysine at position 601, yield-
ing the BRAF V600DK601del mutant protein.
In silico crystal structure analysis
At the time of our analysis, the complex BRAF V600DK601del
mutation had not been reported in the literature. Conse-
quently, no information on the potential vemurafenib re-
sponse for this mutation was available.
To establish whether p.V600_K601delinsD BRAF
mutation-positive melanoma might be sensitive to treat-
ment with vemurafenib, we performed a crystal struc-
ture analysis of BRAF proteins using Sybyl®-X software(Tripos, MO, USA). The following structures from the
PDB database [21,22] were used: 4E4X [23] and 3OG7
[14]. The Sybyl®-X software’s Biopolymer module was
used to prepare, visualize, superimpose and compare
the two crystal structures. Graphics were prepared with
the PyMOL Molecular Graphics System (Schrödinger,
OR, USA). As illustrated in Figure 5A and 5C, the activa-
tion segment (in blue) of BRAFWT kinase domain holds
the protein in an inactive conformation through associ-
ation with the P-loop (in dark green) via predominantly
hydrophobic interactions [13]. The V600 and K601 resi-
dues are located in the BRAF kinase domain’s activation
segment. In the BRAFV600E mutant, the medium-sized
hydrophobic amino acid residue valine is replaced by the
large, negatively charged glutamic acid residue; this dis-
rupts the interaction between the P-loop and the activa-
tion segment (Figure 5B). In turn, this destabilizes the
inactive conformation and promotes an active conform-
ation with increased kinase activity [13]. In all BRAFV600E
kinase domain crystal structures, the atomic coordinates
for activation segment region (K601-S614) have not been
fully resolved by X-ray diffraction analysis (Figure 5D) -
probably due to increased flexibility or even structural dis-
order caused by the mutation. The same can be expected
of BRAFV600DK601del mutant protein because of the
physical-chemical similarity between aspartic acid and glu-
tamic acid residues. This observation is also consistent with
in vitro studies showing that (i) both V600E and V600D
mutants have similar, elevated levels of kinase activity [13]
Figure 4 Schematic representation of monoallelic, biallelic and biclonal mutations and their therapeutic consequences. Mutations
identified by molecular biology analysis of a DNA sample may reflect three distinct molecular events in tumor cells within a single tumor.
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of melanoma cell lines expressing BRAFV600D [24].
We next considered the impact of K601 deletion.
When comparing the structure of BRAFV600E cocrystal-
lized in the presence of vemurafenib (PDB: 3OG7) with
BRAFWT cocrystallized with another selective inhibitor
(T1Q) (PDB: 4E4X), it can be seen that the distance be-
tween K601 and the sulfonyl group of both inhibitors is
more than 10 Å (Figure 5C) - suggesting that K601 does
not participate in ligand binding. Moreover, the lack of
an electron density map for the region including E600
and K601 in the vemurafenib-BRAFV600E complex also
suggests that neither of these residues is crucial for
protein-ligand interaction. In view of the above argu-
ments, we expected the BRAFV600DK601del mutant pro-
tein to be sensitive to inhibition by vemurafenib.
Discussion
Here, we reported on use of the BRAF tyrosine kinase
inhibitor vemurafenib to treat a patient with a rare,complex BRAF mutation (p.V600_K601delinsD). To the
best of our knowledge, only two other patients harboring
the same mutation have been reported to date [7,25].
Only one of the two patients was treated with vemurafe-
nib, and the response was good [25]. The present case is
therefore the second to display a positive response.
At the time of molecular diagnosis, the p.V600D muta-
tion and the p.K601 deletion had been individually and in-
dependently described by different researchers [1,4,11,26];
this suggested that the mutations were present on two dif-
ferent alleles, with the expression of two mutant proteins
(BRAFV600D and BRAFK601del). Furthermore, the presence
of several distinct BRAF gene mutations in the same mel-
anoma tissue sample has been reported [9,27-29]. How-
ever, none of the latter reports distinguished between
monoallelic and biallelic mutations or commented on
their possible biclonal nature.
To establish whether our patient’s mutations were
monoallelic (BRAFV600DK601del) or biallelic (BRAFV600D

















Figure 5 Crystal structures of BRAF domain-inhibitor complexes. (A) BRAFWT and T1Q (in yellow), (B) BRAFV600E and vemurafenib (in light
blue), (C) comparison of binding modes of the two inhibitors, and (D) multiple sequence alignment of crystallized BRAF domains (amino acids
residues lacking electron density are represented by dots. The BRAF domain structural regions are colored as follows: green: P-loop; red: hinge
region; blue: activation segment; cyan: DGF motif; lime: α-C-helix; magenta: α-E-helix.
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of the mutations revealed that the two changes were
monoallelic (Figure 3), resulting in a p.V600_K601delinsD
mutant protein. Busser et al. and Heinzerling et al. did not
perform allele discrimination experiments and so could
not reasonably assume that the mutation resulted in
BRAFV600_K601delinsD [7,25]. To the best of our knowledge,
the present report is the first to show that both mutations
occur within the same allele.
There are almost no literature data on the response to
vemurafenib for tumors with complex BRAF mutations
(probably because of their low incidence). In order to
analyze the potential effects of the mutation on vemurafe-
nib binding, we performed an in silico crystal structure
analysis (Figure 5). Based on the structures of BRAFV600E
cocrystallized in the presence of vemurafenib and BRAFWT
cocrystallized with T1Q, we forecast that the protein
encoded by the mutant allele BRAFV600_K601delinsD would be
sensitive to vemurafenib inhibition. The resolved crystalstructures do not provide information on the impact of
the K601del mutation on the flexibility of the activation
segment. A more precise answer would require molecu-
lar dynamic simulations based on the model structure
of the kinase domain bearing the complex mutation.
This type of modelling might reveal the impact of the p.
V600D_K601del mutation on activation segment flexi-
bility and might enable estimation of the free energy of
vemurafenib binding in the presence and absence of the
K601 residue.
Nevertheless, our current modelling predictions are in
agreement with the patient’s positive treatment response;
vemurafenib therapy was associated with a rapid, object-
ive, clinical response and 2 months of PFS. Our present
observations are consistent with data shown in phase I, II
and III clinical trials in which patients with an objective
response to vemurafenib display disease progression two
months after starting the treatment [15,16,30]. Our data
suggest that the rare mutation BRAFV600_K601delinsD is
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and should respond to BRAF inhibitors in the same way
as the classic p.V600E mutation. In a more general way,
performing predictive in silico structural analysis before
the treatment is started could be helpful to evaluate the
activating character of a mutation when the clinical effi-
cacy is not well established. Moreover, this approach is
currently being used in the French clinical trial AcSé
crizotinib [31].
Interestingly, the p.V600_K601delinsD mutation was
originally misidentified by the primer extension method
as p.V600E. This is explained by the fact that the for-
ward extension primer for V600E specifically targets the
second nucleotide (T) in codon 600 (GTG), which in our
case was also substituted for an A (GAT), as in the V600E
mutation (GAG). However, in a retrospective study of 47
metastatic melanoma from our centre, we have compared
the V600 mutation detection by molecular techniques
with the BRAFV600E mutant protein expression by immu-
nohistochemical analysis using highly specific anti-
BRAFV600E monoclonal antibodies and no other cases of
misidentified p.V600E mutation was found [32].
Since treatment of BRAF-mutated patients has a pro-
found impact on disease and overall survival, the accur-
ate diagnosis of rare BRAF mutations is crucial and
must be correlated with documented reports on clinical
benefits. However, this type of mutation might not be
detected with certain mutation-specific assays [7,33];
consequently, affected patients might be excluded from
clinical trials with BRAF inhibitors or regular treatment
with vemurafenib [16]. The choice between mutation-
specific detection methods (which are rapid and highly
sensitive, with detection of fewer than 5% of tumor cells in
a normal background) and sequencing-based methods
(which are extensive but also labor-intensive and/or less
sensitive) is a recurrent dilemma for molecular biologists
in the field of oncology. Indeed, care should be taken
when choosing an approach for molecular testing in clin-
ical practice; the technologies currently available for de-
tecting the V600E mutation differ remarkably in terms of
sensitivity and specificity - especially for rare mutations.
Conclusions
Our experience suggests that (i) patients with a p.
V600_K601delinsD mutation can be treated successfully
with the oral BRAF inhibitor vemurafenib and (ii) molecu-
lar screening should include this type of mutation. New
technological advances in massively parallel sequencing
methods or digital PCR are currently being implemented
in routine diagnostic laboratories and are being validated
for safe use in clinical molecular oncology. These tech-
nologies will doubtless detect many more rare and/or
complex mutations of unknown prognostic, diagnostic
and/or therapeutic significance – thus highlighting theneed for regularly and actively updated clinicobiological
databases that provide the necessary justification for the
therapeutic management of these patients.
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